KalVista Pharmaceuticals, Inc.
Key Metrics
Market Snapshot
About
KalVista Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company focused on discovering, developing, and commercializing small molecule protease inhibitors. The company's primary focus is on developing oral treatments for hereditary angioedema (HAE), a rare genetic disorder causing painful and potentially life-threatening swelling attacks. KalVista's pipeline includes both on-demand and prophylactic therapies targeting plasma kallikrein, a key enzyme in the HAE disease pathway. The company is advancing multiple clinical-stage programs aimed at providing more convenient treatment options for HAE patients.